ArticleMetabolites2026
Multi-Modal Metabolomics Deciphers Pan-Cancer Metabolic Landscapes and Spatial-Niche-Specific Alternations.
Article in Metabolites, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundMetabolic reprogramming is a hallmark of cancer and supports tumor growth and adaptation within the tumor microenvironment (TME). The complexity of this reprogramming manifests as both distinct variations across cancer types and spatial heterogeneity within individual tumors. The specificity of these metabolic alterations, whether to cancer type, spatial niche, or as shared features, remains unclear, highlighting a critical gap in our systematic, pan-cancer understanding of metabolic reprogramming.
methodsWe integrated bulk metabolomics and spatial metabolomics to investigate pan-cancer metabolic features and used blood-based metabolomics and spatial transcriptomics data to validate key findings. Metabolic differences were compared between tumor and normal tissues across multiple cancer types at the bulk level to identify metabolic modules shared across cancers or specific to individual cancer types. A two-step clustering framework was applied to identify both local and global TME-associated spatial metabolic modules of spatial metabolomics data from various tumor tissue slices.
resultsWe have identified a spectrum of metabolic features, including those specific to individual cancer types or spatial architectures and others shared across cancers, with some features emerging only at bulk-level and others uniquely discernible through spatial metabolomics. Integrative analyses also identified 19 metabolites consistently altered in both bulk and spatial data, especially carnitine species, which also showed concordant changes in blood samples and spatial associations with genes involved in fatty acid metabolism.
conclusionsThis pan-cancer, multi-scale integrative analysis highlights substantial metabolic heterogeneity within the TME and across cancer types and identifies metabolites with consistent alterations across analytical layers, providing candidate features for future studies of tumor metabolism and potential metabolic biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.